Cookies on this site

A new technique allowing drugs or vaccines to be encapsulated within tiny biodegradable particles could see an end booster jabs

Multiple injections for vaccinations could become a thing of the past, according to scientists who have developed an approach for delivering many doses of different substances in just one jab.

The technology involves encapsulating drugs or vaccines within tiny particles made of biodegradable polymers. Depending on their makeup, these polymers break down at different points in time, releasing their contents into the body.

Researchers say the approach could allow multiple vaccines to be delivered at once and remove the need for booster jabs. It may also prove handy in treatments for allergies, diabetes and even cancer where multiple injections are needed.

Researchers say it could prove valuable in developing countries, potentially allowing all childhood vaccines and their boosters to be given in one shot.

“One of the main limitations there is access to vaccines and the fact that you have to come back several times in order to get immunity from the pathogen,” said Ana Jaklenec, co-author of the research from the Massachusetts Institute of Technology. “A child or a baby is usually seen once, sometime around the birth time by some sort of healthcare worker.”

Writing in the journal Science, Jaklenec and colleagues describe how they developed the novel technique using biodegradable polymers already approved for use in humans.

The process, they reveal, involves making tiny silicone moulds – rather like ice cube trays – into which the biodegradable polymers are pressed and removed to form an array of box-like structures, each about 400 micrometres across. These are then filled with the required drug or vaccine and allowed to dry.

A lid, made from the same polymer, is then lined up on top of each micro-box and the system is briefly heated to seal it and prevent the drug or vaccine from leaking out.

When injected into the body, the boxes remain sealed until the polymer disintegrates – an event which occurs rapidly, with the timing dependant on the makeup of the polymer itself.

This post originally appears on www.theguardian.com: https://www.theguardian.com/society/2017/sep/14/multiple-time-delayed-drugs-could-be-given-in-single-injection-say-scientists

Similar stories

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

Kintampo Health Research Centre Begin Clinical Trial of Lassa Fever Vaccine in Ghana

The Kintampo Health Research Centre (KHRC) has begun a clinical trial to test a new vaccine candidate against Lassa fever. This is an early-stage (Phase 1b) trial which will primarily assess the safety of the ChAdOx1 LassaJ vaccine and how the immune system responds to it.

Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Similar stories

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

A vaccine candidate developed by scientists at the University of Oxford has been recommended to enter a pivotal Phase 2/3 clinical trial in the Democratic Republic of the Congo (DRC), in a significant step towards tackling Bundibugyo virus, a potentially deadly pathogen for which no vaccine is currently approved.

Kintampo Health Research Centre Begin Clinical Trial of Lassa Fever Vaccine in Ghana

The Kintampo Health Research Centre (KHRC) has begun a clinical trial to test a new vaccine candidate against Lassa fever. This is an early-stage (Phase 1b) trial which will primarily assess the safety of the ChAdOx1 LassaJ vaccine and how the immune system responds to it.

Uganda launches Phase I clinical study of ChAdOx1 BDBV vaccine

Entebbe, Uganda – 6 October 2026 – The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV). The study is part of an international effort to develop vaccines against Ebola virus species for which no licensed vaccines are currently available.

First volunteer vaccinated in the world's first Bundibugyo ebolavirus vaccine trial

Friday 24th July, Oxford - The University of Oxford’s Oxford Vaccine Group has successfully vaccinated the first volunteer in the world’s first clinical trial of a vaccine designed to protect against Bundibugyo ebolavirus (BDBV).

BD-Ebov trial advances following completion of sentinel vaccinations

The Oxford Vaccine Group has reached an important milestone in the BD-Ebov clinical trial, with the first five participants now vaccinated as part of the study's sentinel group.

World’s first Phase I Bundibugyo ebolavirus vaccine trial launched by Oxford Vaccine Group

Monday 13 July, Oxford: The University of Oxford’s Oxford Vaccine Group has launched the world’s first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.